ARTICLE | Deals
Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others
By Paul Bonanos, Director of Biopharma Intelligence
May 22, 2024 4:50 PM UTC
Biogen’s acquisition of HI-Bio, its second 10-figure M&A deal since the arrival of Christopher Viehbacher as CEO in 2022, will further diversify the company’s pipeline in immunology and rare diseases as part of a continuing push to reshape the organization.
Biogen Inc. (NASDAQ:BIIB) is paying $1.15 billion up front to purchase the South San Francisco company formally known as Human Immunology Biosciences Inc., a privately held start-up that in 2022 acquired rights to programs spun out from MorphoSys AG (Xetra:MOR; NASDAQ:MOR), which Novartis AG (SIX:NOVN; NYSE:NVS) is acquiring for €2.7 billion ($2.9 billion)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652489/biogen-s-pick-and-choose-strategy-in-immunology-leads-to-1b-hi-bio-takeout